Amid growing concern over Korea’s plummeting birthrate, ZP Therapeutics, the commercial arm of Zuellig Pharma, marked World IVF Day on Thursday with an internal event spotlighting its infertility drug and encouraging more open conversations about fertility struggles, including among men.

The event, titled “IVF Hero Day,” aimed to normalize discussions around assisted reproduction and highlight Cyclogest, a progesterone-based treatment that supports implantation and helps sustain pregnancy following in vitro fertilization. IVF is a process in which an egg is fertilized outside the body and then transferred to the uterus.

One employee who conceived through IVF after using Cyclogest spoke about her experience during a panel session. She was joined by male colleagues who shared their own perspectives on fertility, a topic still considered taboo in many parts of Korean society.

“Infertility is a societal issue that we must overcome together in this era of declining birthrates,” said Kim Jung-hun, country leader of ZP Therapeutics. “We will continue to collaborate with trusted global partners in women’s health to ensure that Korean patients have better access to the treatments they need.”

Zuellig Pharma Korea noted that 53 percent of its senior leadership roles are held by women and said it remains committed to fostering a workplace grounded in gender balance, diversity, equity, and inclusion.